Education
About Us
Working with TipRanks
Follow Us
Mesoblast Ltd (MESO)
NASDAQ:MESO
MESO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.09 - $22.00
Previous CloseN/A
Volume155.35K
Average Volume (3M)263.53K
Market Cap
$2.07B
Enterprise Value$1.35B
Total Cash (Recent Filing)$38.03M
Total Debt (Recent Filing)$126.11M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Feb 26, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding127,996,720
10 Day Avg. Volume351,507
30 Day Avg. Volume263,530
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue238.47
Enterprise Value/Gross Profit-59.92
Enterprise Value/Ebitda-27.36
Forecast
1Y Price Target
$27.00Price Target Upside70.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Financial PerformanceRyoncil launch progressing well with strong initial progress, generating $13.2M in gross revenues and achieving 90% gross margins.
Market ExpansionExpansion plans for Ryoncil include targeting adult severe steroid-refractory acute graft versus host disease, potentially tripling the current market size.
Regulatory ProgressPositive feedback from the FDA on potential accelerated BLA filing for rexlemestrocel in chronic heart failure indicates promising regulatory progress.
Bears Say
Debt And FinancingA convertible note subscription agreement allows Mesoblast to issue up to $50M in funding, providing financial flexibility to repay secured debt and fund operations.
Regulatory ChallengesMesoblast is on track to file for accelerated approval by the end of the year, positioning the company for approval next year.
Mesoblast News
MESO FAQ
What was Mesoblast Ltd’s price range in the past 12 months?
Mesoblast Ltd lowest stock price was $7.09 and its highest was $22.00 in the past 12 months.
What is Mesoblast Ltd’s market cap?
Mesoblast Ltd’s market cap is $2.07B.
When is Mesoblast Ltd’s upcoming earnings report date?
Mesoblast Ltd’s upcoming earnings report date is Feb 26, 2026 which is in 152 days.
How were Mesoblast Ltd’s earnings last quarter?
Mesoblast Ltd released its earnings results on Aug 28, 2025. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.373 by -$0.057.
Is Mesoblast Ltd overvalued?
According to Wall Street analysts Mesoblast Ltd’s price is currently Undervalued.
Does Mesoblast Ltd pay dividends?
Mesoblast Ltd does not currently pay dividends.
What is Mesoblast Ltd’s EPS estimate?
Mesoblast Ltd’s EPS estimate is -0.23.
How many shares outstanding does Mesoblast Ltd have?
Mesoblast Ltd has 127,996,720 shares outstanding.
What happened to Mesoblast Ltd’s price movement after its last earnings report?
Mesoblast Ltd reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.373. Following the earnings report the stock price went down -13.292%.
Which hedge fund is a major shareholder of Mesoblast Ltd?
Currently, no hedge funds are holding shares in MESO
Mesoblast Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.00 (70.24% Upside)
$27.00 (70.24% Upside)
Blogger Sentiment
Bullish
MESO Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Decreased
By 12.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.4%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
133.66%
12-Months-Change
Fundamentals
Return on Equity
-18.96%
Trailing 12-Months
Asset Growth
17.27%
Trailing 12-Months
Company Description
Mesoblast Ltd
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
MESO Company Deck
MESO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call illustrated significant growth and successful product launch achievements, particularly with Ryoncil's market penetration and FDA approval. However, increased operational expenses and revaluation-related losses presented financial challenges. Overall, the company's positive strides in market access and regulatory feedback indicate strong potential for future growth.View all MESO earnings summariesMESO Stock 12 Month Forecast
Average Price Target
$27.00
▲(70.24% Upside)
Technical Analysis
Sarepta Therapeutics
―
Cogent Biosciences
―
Adaptive Biotechnologies
―
Harmony Biosciences Holdings
―
Immunocore Holdings
―
Ownership Overview
―
Insiders
0.02% Mutual Funds
0.61% Other Institutional Investors
98.94% Public Companies and
Individual Investors